Active Biotech AB (publ) (FRA:BTPC)

Market Cap	16.18M +99.7%
Revenue (ttm)	n/a
Net Income	-3.45M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	10.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	209,420
Open	0.0058
Previous Close	0.0061
Day's Range	0.0058 - 0.0058
52-Week Range	0.0016 - 0.0307
Beta	n/a
RSI	52.48
Earnings Date	May 7, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvir...

• Industry: Pharmaceutical Preparations
• Founded: 1983
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BTPC

Financial Performance

Financial numbers in SEK